EHA 2022

Conference Coverage

Zandelisib Displays “Exemplary” Efficacy in Relapsed/Refractory Follicular Lymphoma

Tisagenlecleucel Demonstrates Activity in Young Patients With R/R Non-Hodgkin Lymphoma

Obinutuzumab Bests Rituximab in Previously Untreated Follicular Lymphoma

Predicting Response to COVID-19 Vaccines in Patients With Hematologic Malignancies

Extended Decitabine Appears Safer Than Standard Induction for Older AML Patients

Response to Axicabtagene Ciloleucel Superior to Standard Care in R/R Large B-Cell Lymphoma

Venetoclax Plus Obinutuzumab May Improve PFS, Not OS in Chronic Lymphocytic Leukemia

Bortezomib Provides No Benefit Over R-DHAP Alone in R/R DBLCL

Orelabrutinib-Sintilimab Yields Responses in Primary CNS Lymphoma

DA-EPOCH-R No More Effective Than R-CODOX-M/R-IVAC in Burkitt Lymphoma

Momelotinib Bests Danazol in Symptomatic, Anemic Myelofibrosis

Quizartinib Improves Overall Survival in FLT3-ITD+ Acute Myeloid Leukemia

Academic BCMA CAR T-Cell Therapy “Promising” in Rel/Ref Multiple Myeloma

Blinatumomab Linked to Higher Costs, Hospitalizations for R/R ALL

Guidelines for CML Not Followed in the Real World

Combo Produces High Response Rate in Older Adults With Ph-Negative B-ALL

Triplet Maintenance After HSCT Improves PFS vs Lenalidomide Alone in Multiple Myeloma

Predicting Disease Progression in Patients With MALT Lymphoma

Bacterial Coinfection Associated With Poor COVID-19 Outcomes in Chronic Lymphocytic Leukemia

Study: Nearly One-Third of Children With Hematologic Cancers Develop Cardiotoxicity